Recruiting

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (ADhere)

J2T-DM-KGAD - ClinicalTrials.gov - NCT04250337

The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.
How long will I be in the trial?
The study will last about 16 weeks and may include up to 11 visits.
Email
Recruiting

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (ADhere)

J2T-DM-KGAD - ClinicalTrials.gov - NCT04250337

The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.
How long will I be in the trial?
The study will last about 16 weeks and may include up to 11 visits.
Email

Key Requirements

Age :

12+

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

12+

Sex

All

Participants must

Participants must have atopic dermatitis that has been present for at least one year

Participants must have had an inadequate response to topical medications (medications applied to the skin)

Participants must NOT

Participants must not have received a vaccine within 12 weeks of starting the study

Participants must not have hepatitis

Participants must not have a history of HIV

Participants must not have a history of cancer within 5 years

Women must not be pregnant, breastfeeding or plan to become pregnant during the study

Trial Summary

Conditions the trial is for

Atopic Dermatitis (Eczema), Pediatric Atopic Dermatitis (Eczema)

What the trial is testing?

Lebrikizumab

Could I receive a Placebo?

yes

Enrollment Goal

225

Trial Dates

February 2020 - October 2021

Trial Phase

3

Enter your postal code to find the nearest site

Think this trial might be a good fit for you?

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

12+

Sex

All

Participants must

Participants must have atopic dermatitis that has been present for at least one year

Participants must have had an inadequate response to topical medications (medications applied to the skin)

Participants must NOT

Participants must not have received a vaccine within 12 weeks of starting the study

Participants must not have hepatitis

Participants must not have a history of HIV

Participants must not have a history of cancer within 5 years

Women must not be pregnant, breastfeeding or plan to become pregnant during the study

Trial Summary

Conditions the trial is for

Atopic Dermatitis (Eczema), Pediatric Atopic Dermatitis (Eczema)

What the trial is testing?

Lebrikizumab

Could I receive a Placebo?

yes

Enrollment Goal

225

Trial Dates

February 2020 - October 2021

Trial Phase

3

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?